A system for discovering and producing new tnf receptor releasing enzymes
AssigneeThe Regents of the University of California
InventorsTetsuya Gatanaga, Gale A. Granger
Life of this patent
Estimating the term…
Abstract
The present invention relates to methods of regulating TNF activity indirectly by regulating the activity or concentration of TNF receptor releasing enzyme (TRRE). Preferably, the TRRE activity is regulated local to the site of the condition to be treated. In the case of diseases associated with elevated levels of TNF, such as rheumatoid arthritis, TRRE is administered to the site of inflammation in an amount sufficient to decrease the local levels of TNF. In the case of diseases, such as cancer, that benefit from increased levels of TNF, the level of TRRE is decreased at the disease site.
Claims62
A composition comprising a substantially purified protein having tumor necrosis factor receptor (TNF-R) releasing enzymatic activity, wherein said protein has a native form which exhibits an apparent molecular weight of about 120 kD.
A method of treating a disease associated with elevated levels of soluble tumor necrosis factor receptor comprising administering an amount of an inhibitor of tumor necrosis factor receptor releasing enzyme effective to decrease the levels of soluble tumor necrosis factor receptor.
A composition comprising a substantially purified protein having tumor necrosis factor receptor (TNF-R) releasing enzymatic activity, said protein having a native form which exhibits an apparent molecular weight of about 60 kD.
A method of treating a disease associated with elevated levels of soluble tumor necrosis factor receptor comprising administering an amount of an inhibitor of tumor necrosis factor receptor releasing enzyme effective to decrease the levels of soluble tumor necrosis factor receptor.
Dependencies are inferred from the claim text.